Haemonetics (HAE)
(Delayed Data from NYSE)
$74.77 USD
+0.73 (0.99%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $74.81 +0.04 (0.05%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Haemonetics Corporation has a PEG ratio of 1.28 compared to the Medical - Products industry's PEG ratio of 2.14.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HAE 74.77 +0.73(0.99%)
Will HAE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HAE
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Other News for HAE
XPH: Healthcare Dashboard For July
Haemonetics (HAE) Stock Maintains Outperform Rating by Barrington Research | HAE Stock News
Haemonetics (HAE) Receives Significant Upgrade from Citigroup | HAE Stock News
Haemonetics (HAE) Receives Upgrade as Outlook Improves | HAE Stock News
Haemonetics just upgraded at Citi, here's why